Crescent Biopharma, Inc. (CBIO): Total Liabilities
$37.28M
As of 2025-12-31
$19.50M
As of 2026-06-30
+61.3%
3-year compound annual growth
+20.6%
5-year compound annual growth
+16.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.28M | -20.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $47.10M | +582.3% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $6.90M | -22.3% | 2025-02-13, Balance as of period end |
| 2022-12-31 | $8.88M | -30.3% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $12.74M | -12.8% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $14.61M | +6.1% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $13.77M | +46.9% | 2021-03-02, Balance as of period end |
| 2018-12-31 | $9.37M | +5.6% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $8.88M | +25.3% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $7.09M | -11.3% | 2018-03-06, Balance as of period end |
| 2015-12-31 | $7.99M | +23.7% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $6.46M | +171.9% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $2.38M | n/a | 2015-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $37.28M | -20.8% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $57.01M | +28.3% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $44.74M | +15.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $141.50M | +146.0% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $134.59M | +71.4% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $46.33M | -23.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.58M | -4.7% |
Compare CBIO, JAGX, JANX, ZBIO side by side · Screen every company in Pharmaceutical Preparations ↗